Hepatic and lung methotrexate-associated polymorphic lymphoproliferative disorders arising during postoperative follow-up of renal cell carcinoma: a case report

Abstract Introduction Methotrexate induces lymphoproliferative disorders on rare occasions; however, its pathogenesis remains unknown. A clinical diagnosis based on imaging studies alone is often difficult. Case presentation A 57-year-old Japanese woman was referred to our department for the evaluat...

詳細記述

書誌詳細
出版年:Journal of Medical Case Reports
主要な著者: Yoshi Miyamoto, Chihiro Kawasoe, Kaoru Ito, Nobuyuki Oguri, Takaya Murashima, Toyoharu Kamibeppu, Takahiro Nagai, Hiroki Takamori, Toshio Kamimura, Shoichiro Mukai, Yuichiro Sato, Toshiyuki Kamoto
フォーマット: 論文
言語:英語
出版事項: BMC 2023-12-01
主題:
オンライン・アクセス:https://doi.org/10.1186/s13256-023-04288-z
その他の書誌記述
要約:Abstract Introduction Methotrexate induces lymphoproliferative disorders on rare occasions; however, its pathogenesis remains unknown. A clinical diagnosis based on imaging studies alone is often difficult. Case presentation A 57-year-old Japanese woman was referred to our department for the evaluation of multiple lung and hepatic nodules that developed during methotrexate treatment for rheumatoid arthritis. Since she had a history of nephrectomy for localized renal cell carcinoma, multiple lung and hepatic metastases were initially considered. However, pathological diagnosis of the lung nodules (needle biopsy) revealed methotrexate-associated polymorphic-type lymphoproliferative disorders. After methotrexate discontinuation, continuous smooth shrinkage of the lung and liver lymphoproliferative disorders was observed. Conclusion Methotrexate-associated lymphoproliferative disorders should be considered in the event of newly appearing neoplastic lesions, even during follow-up for renal cell carcinoma, if methotrexate is being administered.
ISSN:1752-1947